WO2016180669A1 - Dispositif, système et procédé pour le traitement d'une insuffisance mitrale et/ou tricuspidienne - Google Patents

Dispositif, système et procédé pour le traitement d'une insuffisance mitrale et/ou tricuspidienne Download PDF

Info

Publication number
WO2016180669A1
WO2016180669A1 PCT/EP2016/059839 EP2016059839W WO2016180669A1 WO 2016180669 A1 WO2016180669 A1 WO 2016180669A1 EP 2016059839 W EP2016059839 W EP 2016059839W WO 2016180669 A1 WO2016180669 A1 WO 2016180669A1
Authority
WO
WIPO (PCT)
Prior art keywords
mesh
frame
valve
leaflet
atrium
Prior art date
Application number
PCT/EP2016/059839
Other languages
English (en)
Inventor
Stefan Schreck
Original Assignee
Jenavalve Technology Gmbh
Jenavalve Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenavalve Technology Gmbh, Jenavalve Technology, Inc. filed Critical Jenavalve Technology Gmbh
Publication of WO2016180669A1 publication Critical patent/WO2016180669A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2454—Means for preventing inversion of the valve leaflets, e.g. chordae tendineae prostheses

Definitions

  • the present disclosure relates generally to systems and methods for the treatment of a mitral or/and tricuspid valve insufficiency.
  • the mitral and the tricuspid valve are positioned at the inflow of the left and right ventricle respectively. They open during diastole to allow blood from the according atrium to fill the left and from right ventricle respectively. They close during systole to prevent blood from flowing back into the atrium.
  • Leaky mitral or tricuspid valve reduce the pumping efficiency of the heart and can lead to heart failure and in some cases even to patient death. It is therefore generally recommended to treat leaky valves in order to improve or restore normal heart function.
  • Mitral regurgitation has for example two main causes.
  • degenerative MR the chordae are elongated or ruptured. As a result, sections of the posterior or anterior leaflet or both can prolapse into the atrium. This may create a lack of coaptation between the posterior and anterior valve.
  • functional MR the left ventricle enlarges or changes shape. This can cause the papillary muscles to misalign with respect to the annulus.
  • the chordae which are anchored in the papillary muscle may pull on the leaflets during systole and prevent the leaflets from touching and coapting properly.
  • the causes for tricuspid regurgitation are similar to that of MR.
  • Mitral repair techniques have been developed to treat degenerative MR.
  • the segment of the leaflet that has elongated and ruptured chordae is resected and the adjacent segments of the leaflet are sewn together.
  • the annulus is typically slightly reduced and stabilized by sewing an annuloplasty ring or band onto the inflow rim of the valve.
  • the Alfieri stich or edge-to-edge procedure is an alternative surgical technique in which the free margin of the diseased segment of the posterior leaflet is connected to the free margin of the opposing anterior leaflet or vis versa.
  • the healthy chordae of the opposing leaflet then supports the free margin of the diseased leaflet.
  • the Alfieri stich is effectively a chordae sharing procedure.
  • the entire mitral valve may be replaced by a valve prosthesis.
  • the leaflets are usually surgically removed and a mechanical or bioprosthetic valve prosthesis is sewn to the annulus. Mechanical valve
  • mitral valve repair may be preferred over mitral valve replacement.
  • mitral and/or tricuspid valve repair techniques have been developed to repair mitral and/or tricuspid valves. Advancements in this field have been hampered by the complexity of the surgical techniques and the lack of visual access to the according valve. There is a need for alternative mitral and tricuspid valve repair techniques, including devices that may be delivered trans-apical and trans-vascular.
  • a mitral and/or tricuspid repair technique is provided that can be delivered surgically through the open arrested heart, or trans-apically or trans-vascularly to a beating heart.
  • a method is provided for the repair of leaking mitral or/and tricuspid heart valve.
  • the system may prevent prolapse of leaflets into the atrium thereby to minimize or eliminate regurgitation of blood into the atrium during systole.
  • Methods are provided to place the system into the heart in order to repair the leaking valve.
  • Fig. 1 at the left side (Fig . la) describes a sectional view of a heart (1) through a normal functioning mitral valve (2).
  • Fig . lb is depicted a degenerative mitral regurgitation (MR), caused by mitral valve prolapse into an atrium (4).
  • MR degenerative mitral regurgitation
  • Fig . lc is another degenerative MR
  • the chordae (3) may be elongated or ruptured.
  • sections of the posterior or anterior leaflet (5,6) or both may prolapse into the atrium (4). This may create a lack of coaptation between the posterior (6) and anterior (5) valve.
  • the left ventricle may enlarge or change shape. This may cause the papillary muscles (7) to misalign with respect to the annulus.
  • the chordae (3) which are anchored in the papillary muscle (7) may pull on the leaflets during systole and prevent the leaflets from touching and coapting properly.
  • Fig. 2 depicts the anatomy of a mitral valve and the treatment of mitral valve regurgitation according to some current techniques.
  • the mitral valve (2) as shown is shaped like the letter D with the straight section located adjacent to the aortic valve.
  • the mitral valve has two leaflets (5, 6).
  • the anterior leaflet (5) is hinged along the straight section of the D
  • the posterior leaflet (6) is hinged along the curved section of the D.
  • the posterior leaflet (6) is further divided into three segments PI (6'), P2 (6") and P3 (6"') with PI (6') being most lateral and P3 (6"') being most medial .
  • the opposing segments of the anterior leaflets (5) are referred to as Al (5'), A2 (5") and A3 (5'")- Chordae tendenae (3) connect the leaflets (5, 6) to the papillary muscles (7) in the left ventricle.
  • the chordae (3) support the leaflets (5, 6) similar to the cords of a parachute supporting the parachute. Without the chordae (3), the leaflets (5, 6) would prolapse into the atrium during systole.
  • Fig. 2a illustrates a normal mitral valve with no insufficiency.
  • Fig. 2b depicts a flail posterior leaflet (6) causing mitral valve insufficiency.
  • Mitral repair techniques have been developed to treat degenerative MR.
  • the segment of the leaflet (5, 6) that has elongated and ruptured chordae (3) is resected .
  • Fig. 2c shows a resection of flail segment.
  • the adjacent segments of the leaflet (6) are usually sewn together.
  • the annulus is typically slightly reduced and stabilized by sewing an annuloplasty ring (9) or band onto the inflow rim of the valve.
  • Fig. 5 illustrates a system for treatment of a mitral or/and tricuspid valve insufficiency according to an embodiment of the present disclosure.
  • a mesh (8) is disposed over an inflow area of the valve, which is shown for illustration purposes as a mitral valve (2).
  • Fig. 3 the mesh (8) itself is shown in a top view (Fig . 3a) and a sectional view (Fig. 3b).
  • FIG. 6 shows a schematic view of a damaged mitral valve and a system for treatment according to an embodiment of the present disclosure. It is depicted a mitral valve (2) wherein for one leaflet (5, 6) the chordae (3) is ruptured . As a result sections of the leaflet (5,6) prolapse into the atrium (4).
  • Fig. 7 shows how a system for treatment of a mitral valve insufficiency, which might also be used for tricuspid insufficiency, according to some embodiments of the present disclosure is provided. As shown, a mesh (8) is disposed at least over a portion of an inflow area of the valve.
  • a frame (10) of the mesh (8) is at least partially located in an atrium (4) and at least partially engaged with the mesh (8).
  • this system it can be achieved that during diastole blood passes through mesh openings and during systole at least one valve leaflet (5, 6) contacts the mesh (8) thereby preventing the leaflet (5, 6) from prolapsing into the atrium (4).
  • Fig. 8 illustrates this in more detail .
  • Fig. 9 illustrates a sectional view of a mesh (8) according to an embodiment of the disclosure.
  • the frame (10) is provided in a manner, that it comprises two zones.
  • the "inner zone” or core (13) of the frame exhibits a relatively higher rigidity that the "outer zone” (14) of the frame.
  • the "inner zone” or more rigid part (13) of the frame (10) may ensure that the frame (10) keeps the correct form in the target.
  • the “outer zone” or softer part (14) of the frame (10) may be made from a relatively softer material and may allow e.g. for needle penetration for placement of surgical sutures.
  • Fig. 10 shows sutures (15) placed along the circumference of the frame to secure the mesh to the annulus of the mitral valve.
  • Fig. 11 is another variation of the system according to the present disclosure wherein anchoring means (11), here shown as hooks, are provided to secure the frame (10) and/or mesh (8) in a position in the heart, when introduced in a target.
  • anchoring means 11
  • Fig. 11 is another variation of the system according to the present disclosure wherein anchoring means (11), here shown as hooks, are provided to secure the frame (10) and/or mesh (8) in a position in the heart, when introduced in a target.
  • Fig . 12 shows another variation of an embodiment of the present disclosure.
  • the frame (10) may be expandable, e.g ., to secure position when introduced to a target.
  • Fig . 13 shows the expandable frame (10) in a final position in the atrium (4).
  • the frame can be introduced to a target and then when it is in the right position the frame may be expanded and therefore secured in its position.
  • Another possibility to secure position of the mesh (8) in the target is illustrated in Figs. 14 and 15.
  • a cage like formation is arranged at the mesh (8) as an anchoring means (11). Also this cage-like formation may secure the mesh (8) and frame (10) in the atrium (4).
  • Figs. 16 to 21 show other exemplary embodiments of securing the frame (10) and mesh (8) in a final position in the target.
  • the mesh is provided with connection points (16) for anchoring means (11).
  • These anchoring means (11) comprise at least a tether (12) that liaises the frame (10) and/or mesh (8) with a left ventricular wall (Fig . 17), the Apex and/or a papillary muscle (7); see Fig. 19.
  • Fig. 17 and 18 show exemplary embodiments of the anchoring elements (17) of the anchoring means (11), provided according to this
  • Fig . 17 may be used in transapical and transvascular (e.g., transfemoral) implantation methods whereas the embodiment shown in Fig . 18 is generally suitable for transapical implantation methods.
  • connection points (16) of anchoring means (11) are depicted in Figs. 20 and 21.
  • the mesh is omitted here and only the frame (10) is shown.
  • exemplary points (16) at which the anchoring means pass through the mitral valve are provided. Passing the anchoring means through the mitral valves at the commissures between the leaflet segments may minimize interference between the anchor means and the closed mitral leaflets.
  • two connection points (16) are provided, but in this example the connection points (16) are supported by the frame (10) and arranged so that in final position of the system in the target the connection points (16) are arranged on commissures (18) of the valve (2).
  • the frame (10) may be C-shaped with an opening (19) toward the anterior side (see e.g. Fig . 22). These openings can help to minimize interference of the implanted mesh (8) and frame (10) with the aortic valve.
  • the mesh (10) may not completely fill the space within the frame (10) but only cover selected areas within the frame.
  • Fig. 23 shows a mesh cut out of a sheet material and where mesh (8) and frame (10) are built of the same sheet material.
  • Figs. 24 to 27 show means for self- centering (20) on two lateral sides of the frame (10) only, whereas Figs. 25 to 27 illustrate several self-centering means (20) arranged circumferentially at the frame (10).
  • the embodiment illustrated in Fig. 27 further shows connection points (16) as already described in connection with Fig. 21, e.g ., the connection points (16) being arranged on commissures (18) of the valve (2).
  • Figs. 28 to 30 show another embodiment of the disclosure.
  • the frame (10) supports an anterior mesh (8a) and a posterior mesh (8b).
  • Each mesh has connecting points (16) for anchoring means (11) to anchor the mesh (8a, 8b) in the left ventricle.
  • two struts (22) span across the frame (10), whereas each strut (22) provides a connecting point (16) for anchoring (11) means to anchor the frame (10) in the left ventricle.
  • Figure 29 shows a side view of the embodiment in Figure 28 illustrating the anchoring means (11).
  • the anchoring means (11) may comprise, for example, one or more tethers, cables, or strings, or any combination thereof.
  • the anterior mesh (8a), the posterior mesh (8b), and the frame (10) may be anchored with their own respective anchoring means (11).
  • Fig. 30 shows the
  • Fig. 31 shows the damaged chordae and the prolapse of the P2 (6") leaflet into the atrium.
  • a repair of the prolapsing P2 segment with a mesh according to an exemplary embodiment of the disclosure is illustrated in Fig. 32.
  • a frame (10) contains a partial mesh (8) only.
  • the arrangement and size of the partial mesh (8) may vary, and may be adapted according to the damage of the valve and/or to minimize the amount of foreign material in the body.
  • three connecting points (16) for anchoring means are provided, one connecting point (16) to anchor the mesh (8) and two connecting points (16) to anchor the frame (10).
  • the next figures illustrate how systems according to the present disclosure may be delivered to a target in a correct position.
  • the mesh (8) and/or the frame (10) may comprise nitinol. Nitinol is a memory alloy(s).
  • the mesh (8) may be provided as a lasercut.
  • Other exemplary materials for the mesh (8) and/or frame (10) include ePTFE, surgical sutures, and/or glass fibres alone or in combination and with or without coatings.
  • Figs. 34 to 36 show examples of the mesh/frame in a catheter (23), and the anchoring means (11) generally aligned to secure correct placement in a target, wherein Fig . 34 shows the entire system still in the catheter (23), Fig. 35 shows the mesh (8) just exiting the catheter (23), and then opening as shown in Fig . 36 while the anchoring means (11) are still aligned in the catheter (23).
  • FIGs. 37 to 44 A delivery of the system in a transapical implantation is illustrated in Figs. 37 to 44.
  • an introducer/catheter (23) may enter the heart in the atrium (4) of the according damaged valve (2). This may be done, e.g ., by using a point (24) which after reaching the desired area, is drawn back (Fig. 39).
  • the rolled up mesh (8) may be pushed out of the introducer (23) (Fig. 40) and the mesh (8) opens (Fig . 41), and then positioned correctly (Figs. 42 and 43).
  • the anchoring means (11) may be anchored by anchoring elements (17) to secure the mesh (8) in place, and the introducer (23) then may be retracted .
  • Another possibility to position the mesh (8) in an introducer may comprise rolling the mesh (8) and then folding it up, e.g. once. This is shown in Fig . 45.
  • Two tethers are shown securing the mesh (8) and may be passed through separate lumens in the introducer (23). This arrangement may help to facilitate the positioning of the mesh (8).
  • FIGs. 46 to 51 A transvascular or transfemoral introduction of a system according to some embodiments of the present disclosure is shown in Figs. 46 to 51.
  • the anchoring elements (17) may be anchored . In the example as depicted in Fig. 46 this may be done by helical fasteners.
  • the introducer (23) then may be guided through the valve (2) to the atrium (4) (Fig. 47).
  • the mesh (8) may be pushed out of the introducer (23) (Fig. 48) and positioned correctly (Fig. 49).
  • the anchoring elements (17) may be fixed to the connection points (16).
  • This can for example be provided by a clip (25) or a suture lock, for example, so that the length of the anchoring means (11) can be adapted and the mesh (8) therefore secured in its correct position (Fig . 50). At the end the introducer (23) may be retracted (Fig. 51).
  • Mitral valve insufficiency and/or tricuspid valve insufficiency as described in connection with the present disclosure generally refers to leaky mitral or tricuspid valves, respectively, which reduce the pumping efficiency of the heart and therefore may lead to heart failure, and potentially patient death. Accordingly, leaky valves may be treated in order to improve and/or restore normal heart function. While certain embodiments, examples, and descriptions herein relate to mitral valve insufficiency the skilled person will understand that the present disclosure applies equivalently also to tricuspid valve insufficiency and the according system and treatment.
  • the expression "mesh” according to the present disclosure includes any kind of materials and configurations of materials having structures with openings, e.g ., to prevent leaflets to prolapse but on the other hand to let pass blood into the valve during the diastole.
  • the structure of the mesh may have any kind of suitable appearance, shape, or configuration. Also the mesh may only cover parts of the leaflets, e.g., depending on the nature of the malfunction and/or the design as may be advantageous.
  • the mesh in the sense of the present disclosure does not need to be a mesh in a classical sense; the skilled person will appreciate that any design of a means will be useful in the sense of the disclosure which allows for retaining the damaged leaflet(s) in or at the endogenous level when closed and/or for preventing prolapse into the atrium. Accordingly, in some embodiments it may suffice that the frame in the inside is connected by more or fewer elements, for example only a few connector means, such as, e.g., 3, or as many as 100 or more connector means.
  • the connector means may have a diameter of 0.001 to 1.0 mm, such as 0.01 to 0.2 mm.
  • Such connector means may be positioned to cross each other and/or may be parallel, e.g., designed to connect the frame in a parallel manner.
  • the connector means may be positioned with a distance of between 0.1 and 20 mm.
  • the mesh may comprise open cells, which may be woven, cut, and/or provided in any other manner.
  • the open cells may have a diameter of diameter of between 0.1 and 20 mm, such as 1.0 and 10 mm, or 0.1 and 5 mm.
  • the device may comprise a single sheet with an integrated frame.
  • the mesh may be made from a nitinol sheet wherein the cells are laser cut out, e.g., to provide for blood flow through the mesh upon deployment (cf. e.g.
  • the mesh may provide a smooth surface, e.g., without sharp edges or ridges, for example to minimize abrasion of tissue etc. when placed in the target.
  • the mesh may comprise a coating, e.g., to smoothen the surface, e.g ., a PTFE coating.
  • frame as used in the present disclosure includes any kind of partial or entire circumferential surrounding of the mesh and/or connector means.
  • the frame may include just the circumference of the mesh but also may include a frame produced differently, e.g., showing different features and characteristics (like rigidity, etc).
  • embodiments of the present disclosure may represent the means to position the device (e.g ., as represented by mesh and frame) on the valve and moreover it may represent a means for fixation of the device in its functional position for valve repair.
  • the frame may also have the same thickness as the mesh or it may be bended and/or have a certain dimension, e.g., and thus may take a certain space in the atrium (cf. e.g. Fig 13) which may be usefu l for positioning and/or holding the device in the correct position.
  • the frame can thus contribute to a self-positioning or self-centering of the device.
  • the frame may have a dimension of 5 to 20 mm into the atrium.
  • the mesh may be 0.1 to 1 mm in thickness and the frame may be 5 to 20 mm.
  • the frame in addition to the frame as an outer boundary of the mesh, e.g., representing its limitation, the frame can be connected to and/or can be designed as a cage. For example, when positioned for repair the cage may contribute to a correct positioning and maintaining the correct position of the device for correct repair function (cf. e.g . Fig 14, 15). In some
  • the frame may thus also be denoted a self-centering frame (cf. e.g. Fig. 24, 25).
  • “partially engaged” as used herein includes any kind of connection and includes also embodiments wherein two parts are built as one part, e.g ., and as used above with the term device.
  • sheet material As one example of material for use for the mesh according to an embodiment is mentioned "sheet material”. This includes any kind of material(s) being in a sheet or sheet-like form, e.g., and suitable for the use as implant. This also includes memory materials, which after a possible minimal invasive introduction in the heart may have a predetermined form without any further adjustments.
  • a cutting process including, but not limited to, laser-cutting may be suitable here.
  • anchoring means includes any kind of means which secure the mesh and/or frame in a position.
  • the frame itself may be provided in a manner to anchor, such as, e.g. by using a relatively rigid material to connect to the mesh and circumferentially a relatively soft or softer material which might be deformed when placed in the atrium and therefor anchors the frame/mesh.
  • the same may be achieved by an expandable frame in some embodiments.
  • the frame and/or mesh may comprise at least one element chosen from the group of sutures, clips, screws, and/or hooks, which may be anchored in the atrium.
  • the mesh and/or frame may be connected by tethers with anchoring elements (like, e.g., sutures, clips, screws, and/or hooks) so that as another possibility the anchoring may be elongated from the position of the mesh and/or, for example, in the apex or left ventricle, respectively.
  • anchoring elements like, e.g., sutures, clips, screws, and/or hooks
  • the above mentioned “tether” includes any kinds of connections between the frame/mesh (device) and the anchoring elements.
  • “Introducer” includes a means to be used depending on, e.g., the surgery to transport the mesh/frame/device to the desired target position.
  • the introducer may include a kind of catheter which is suitable to be used in minimal invasive surgery.
  • the introducer may include any kind of suitable means.
  • the introducer when minimal invasive surgery is applied, may be suitable to receive the mesh and/or frame/device. This can be, for example, accomplished by rolling up the mesh and/or frame/device in the introducer.
  • the introducer may comprise a holding means, e.g., for maintaining the device in a rolled up and/or folded form exhibiting a relatively small diameter/volume during introduction through the vasculature or the apex in transapical application, a means for guiding the device through the vasculature to the target site, a handle for operating the guiding and release of the device to and at the target site.
  • the handle may comprise connector means for operating the holding means, e.g., to be able to release the device at the target site. Any other terms used in the following will be understood by the skilled person in the art and in the usual sense and manner usually applied in the art.
  • the device as disclosed herein may provide for repair of a valve malfunction, such as a mitral valve malfunction.
  • the device as disclosed herein may be designed in a manner to be applicable in a minimally invasive manner to the target site, which in general may include the
  • the device as disclosed in a minimalistic embodiment may exhibit one or more means to inhibit or prevent valve leaflet(s) from prolapse into an atrium, and thus may restores to a certain degree or substantially completely the natural valve function.
  • the device in general may comprise a means for retaining the valve leaflets at a certain position, and/or a means for positioning and/or retaining itself at the target site to exert its function, e.g., its valve repair function.
  • the means for retaining the leaflets may be denoted mesh and the means for positioning and/or retaining the device in place may be denoted frame.
  • the combination may be also denoted device or system.
  • the disclosure relates to a system for treatment of a mitral or/and tricuspid valve insufficiency, wherein the system may comprise a mesh disposed at least over a portion of an inflow area of the valve upon implantation. Further, the system may comprise at least a partial frame which is at least partially located in an atrium and at least partially engaged with the mesh. The system further may be provided so that during diastole blood passes through mesh openings and during systole at least one valve leaflet contacts the mesh, e.g., thereby preventing the leaflet from prolapsing into the atrium.
  • the mesh may inhibit or prevent the leaflet from prolapsing into the atrium.
  • the valve may function in a way as desired that leaflets are touching and therefore coapting properly.
  • the valve may close during systole and may prevent blood from flowing back into the atrium.
  • pumping efficiency of the heart may be efficient or otherwise improved.
  • the mesh and the frame can be formed of different or the same material.
  • the use of different materials for the mesh and the frame may be advantageous in some cases, e.g., to provide different properties. In case they are of the same material it may be advantageous if the mesh and frame are produced in one step and as one component. Such an embodiment may facilitate the production of the mesh and frame.
  • the mesh and frame may be cut of a sheet material, e.g., one sheet material. This may lead to lean and therefore cost effective production process.
  • anchoring means to secure the frame and/or mesh in a position.
  • the anchoring means By providing the anchoring means the mesh and/or frame can be positioned in a desired position and secured in this position.
  • the frame and/or mesh can be secured to the heart and/or an annulus of the valve.
  • the anchoring means for securing the mesh and/or frame may include an anchoring means which could be of any suitable form.
  • the anchoring means may comprise at least one element chosen from the group of sutures, clips, screws, and/or hooks, and combinations thereof.
  • the anchoring means may comprise at least a tether that may liaise the frame and/or mesh with a left ventricular wall and/or a papillary muscle and there an anchoring means. It was found that in certain situations it may be of benefit if the tethers are arranged to pass through the closed valve along a line of coaptation of an anterior and posterior leaflet.
  • the frame may be provided as expandable.
  • anchoring of the frame and mesh can be achieved by expanding the frame when positioned correctly after introduction.
  • the mesh and/or frame may comprise any suitable materials and combinations of materials for an implant.
  • the mesh may comprise nitinol, nitrol, surgical sutures, Kevlar fibres, polymeric monofilaments, polymeric braids, wire, ePTFE and/or glass fibers.
  • the mesh and/or frame may be partially or completely pleated and/or deformed for introduction into the heart.
  • a sheet material might be appropriate. The sheet material may be cut by laser-cutting, for example, and further it may be possible to provide the mesh and the frame by cutting the same material accordingly.
  • the solidity of the mesh may be less than 0.05 or 5% respectively, such as less than 0.01 or 1% respectively. Solidity of the mesh may indicate the percentage of an area covered by material of the mesh if the mesh is projected on an area.
  • a method for treatment of a mitral or/and tricuspid valve insufficiency is provided.
  • a mesh may be disposed at least over a portion of an inflow area of the valve.
  • a frame may be disposed at least partially in an atrium and may be at least partially engaged with the mesh.
  • the disposal of the mesh may be provided in such a manner that during diastole blood passes through mesh openings and during systole at least one valve leaflet contacts the mesh. Thereby the leaflet may be prevented from prolapsing into the atrium.
  • the mesh and the frame may be disposed by means of an introducer.
  • the introducer thereby may lead the frame and mesh to a position transapically or transvasculary.
  • the introducer hereby may include a kind of catheter which is suitable to be used in minimal invasive surgery.
  • the implant may be disposed to its position transapically or trans-vascularly to a beating heart.
  • the introducer may comprise a handle comprising operating means for directing the leading and/or positioning of the mesh and/or frame or the device from outside an individual to a defined target site.
  • Some embodiments of the present disclosure may be used for surgery on open arrested heart.
  • the present disclosure relates to a method of deployment of a device for mitral and/or tricuspid valve repair
  • the device may be mounted onto or into a holding means on a catheter (e.g., introducer means) in a relatively small diameter, the catheter may be introduced into the vasculature of an individual and the device may be directed towards the target site.
  • the device may be released by way of the handle of the catheter, which handle may comprise, and may be connected to, operator means to operate the holding means to release the device to the target site, e.g. by unfolding and/or unrolling the device, and positioning the device to the target site, for example affixing anchoring means in or to the heart.
  • the introducer may be used to lead and/or position the anchoring means.
  • the introducer may be suitable to dispose and/or position the mesh and/or frame in a correct position and further to secure the position by the anchoring means.
  • the mesh and/or frame when supplied to the heart by an introducer the mesh and/or frame may be rolled up in the introducer. Rolling may not substantially influence the form and therefore positioning may be achieved after the mesh/frame are released or pushed out of the introducer.

Abstract

La présente invention concerne des dispositifs, des systèmes et des procédés pour le traitement d'une insuffisance mitrale et/ou tricuspidienne.
PCT/EP2016/059839 2015-05-11 2016-05-03 Dispositif, système et procédé pour le traitement d'une insuffisance mitrale et/ou tricuspidienne WO2016180669A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159430P 2015-05-11 2015-05-11
US62/159,430 2015-05-11

Publications (1)

Publication Number Publication Date
WO2016180669A1 true WO2016180669A1 (fr) 2016-11-17

Family

ID=55910252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/059839 WO2016180669A1 (fr) 2015-05-11 2016-05-03 Dispositif, système et procédé pour le traitement d'une insuffisance mitrale et/ou tricuspidienne

Country Status (1)

Country Link
WO (1) WO2016180669A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226895A1 (fr) * 2019-05-08 2020-11-12 Edwards Lifesciences Corporation Réparation de valve mitrale
US20220079761A1 (en) * 2020-09-11 2022-03-17 The Medical College Of Wisconsin, Inc. Atrioventricular Valve Repair Ring

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027797A1 (fr) * 2003-09-23 2005-03-31 Ersin Erek Dispositif a reseau mitral pour insuffisances de la valvule mitrale
WO2007009609A1 (fr) * 2005-07-15 2007-01-25 Bernal Marco Jose Manuel Anneau prothetique pour chirurgie cardiaque
US20100131057A1 (en) * 2008-04-16 2010-05-27 Cardiovascular Technologies, Llc Transvalvular intraannular band for aortic valve repair

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027797A1 (fr) * 2003-09-23 2005-03-31 Ersin Erek Dispositif a reseau mitral pour insuffisances de la valvule mitrale
WO2007009609A1 (fr) * 2005-07-15 2007-01-25 Bernal Marco Jose Manuel Anneau prothetique pour chirurgie cardiaque
US20100131057A1 (en) * 2008-04-16 2010-05-27 Cardiovascular Technologies, Llc Transvalvular intraannular band for aortic valve repair

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020226895A1 (fr) * 2019-05-08 2020-11-12 Edwards Lifesciences Corporation Réparation de valve mitrale
US20220079761A1 (en) * 2020-09-11 2022-03-17 The Medical College Of Wisconsin, Inc. Atrioventricular Valve Repair Ring

Similar Documents

Publication Publication Date Title
US10849752B2 (en) Methods for anchoring a device at a native heart valve annulus
US11504234B2 (en) Cardiac valve repair system and methods of use
US11826249B2 (en) Devices, systems and methods for heart valve replacement
JP7469395B2 (ja) 埋込可能な心臓弁デバイス、僧帽弁修復デバイス、ならびに関連するシステム及び方法
US20210275305A1 (en) Heart valve leaflet replacement systems and methods for using them
US20200315793A1 (en) Leaflet In Configuration For Function In Various Shapes And Sizes
US20210030542A1 (en) Sequentially deployed transcatheter mitral valve prosthesis
EP3226809B1 (fr) Prothèse de valve segmentée pour implantation transcathéter comprenant un segment de valve non supporté
EP2964152B1 (fr) Prothèse pour implantation transcathéter de valvule
US9326852B2 (en) Method for implanting prosthetic valve
CA2847880C (fr) Prothese de valvule mitrale avec amarres ventriculaires et ses methodes d'implantation
US20160324639A1 (en) Apparatus and methods for treating cardiac valve regurgitation
US20120010700A1 (en) Method for implanting prosthetic valve
US11464635B2 (en) Heart valve with chordal capture elements for stabilization
WO2016180669A1 (fr) Dispositif, système et procédé pour le traitement d'une insuffisance mitrale et/ou tricuspidienne
US20230078372A1 (en) Prosthetic Atrio-Ventricular Valve Systems and Devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16720115

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 09.04.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16720115

Country of ref document: EP

Kind code of ref document: A1